Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2021-02-25 Regulatory Filings
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
Material document(s).pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Heads of Agreement' and details a collaboration agreement between BioVaxys Technology Corp. and ProCare Health Iberia regarding clinical study and commercialization of vaccines and products. It outlines terms of collaboration, responsibilities, intellectual property rights, and governance of the agreement. There is no indication of financial results, audit information, regulatory filings, or other report types. The document is a contractual agreement related to collaboration and development, not a financial or regulatory report. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement or contractual disclosure that does not fit other specific categories.
2021-02-25 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the signing of a Term Sheet between BioVaxys Technology Corp. and BioElpida for clinical-grade bioproduction of a vaccine candidate. It discusses future plans for clinical trials, regulatory approvals, and market potential. There are no financial statements, detailed financial performance data, or regulatory filings such as 10-K or interim reports. The content is primarily an update on a capital/financing or business development activity related to clinical manufacturing and collaboration. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. The document is best classified as a Capital/Financing Update (CAP) because it announces a significant business collaboration and development milestone related to the company's product pipeline and manufacturing capabilities.
2021-02-18 English
News release - English.pdf
Regulatory Filings
2021-02-16 English
News release - English.pdf
Regulatory Filings
2021-02-12 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a broad co-development, joint commercialization, and marketing collaboration between BioVaxys Technology Corp. and Procare Health. It details the terms of the agreement, clinical study plans, marketing rights, and strategic partnership aspects. There are no financial statements, regulatory filings, or detailed financial performance data included. The document is not an earnings release, annual report, or interim report. It is a corporate announcement about a collaboration and investment in clinical studies and marketing rights. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it involves investment and collaboration agreements related to clinical development and commercialization, which are financing and capital-related activities.
2021-02-10 English
News release - English.pdf
Board/Management Information Classification · 100% confidence The document announces the resignation of a company director, Jeremy Poirier, and includes a statement from the CEO thanking him. There is no financial data, no mention of reports, filings, or regulatory bodies. The content is about a change in the company's board of directors. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and focused solely on this announcement, confirming the classification.
2021-02-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.